Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction
Pang, Ran , Zhou, Xinyao , Wang, Xiangling , Yin, Xue-Lai, Hai, Bo , Wang, Bin

Mayo Clinic

Cochrane Database of Systematic Reviews | September 3, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd012336 Get It

Neuropilin-1 modulates interferon-γ-stimulated signaling in brain microvascular endothelial cells
Wang, Ying , Cao, Ying , Mangalam, Ashutosh K. , Guo, Yong , LaFrance‐Corey, Reghann G., Gamez, Jeffrey D., Atanga, Pascal Aliihnui, Clarkson, Benjamin D. , Zhang, Yuebo , Wang, Enfeng , Dutta, Kirthica , Ji, Baoan , Pirko, Istvan, Lucchinetti, Claudia F. , Howe, Charles L. , Angom, Ramcharan Singh , Dutta, Kirthica , Mukhopadhyay, Debabrata , Mukhopadhyay, Debabrata , Howe, Charles L , Guo, Yong , Wang, Ying

Mayo Clinic

Journal of Cell Science | September 2, 2016 | Volume: 129 | Issue: 20 | Pages: 3911-3921

10.1242/jcs.190702 | PMID 27591257 Get It

ABSTRACT Inflammatory response of blood–brain barrier (BBB) endothelial cells plays an important role in pathogenesis of many central nervous system inflammatory diseases, including multiple sclerosis; however, the molecular mechanism mediating BBB endothelial cell inflammatory response remains unclear. In this study, we first observed that knockdown of neuropilin-1 (NRP1), a co-receptor of several structurally diverse ligands, suppressed interferon-γ (IFNγ)-induced C-X-C motif chemokine 10 expression and activation of STAT1 in brain microvascular endothelial cells in a Rac1-dependent manner. Moreover, endothelial-specific NRP1-knockout mice, VECadherin-Cre-ERT2/NRP1flox/flox mice, showed attenuated disease progression during experimental autoimmune encephalomyelitis, a mouse neuroinflammatory disease model. Detailed analysis utilizing histological staining, quantitative PCR, flow cytometry and magnetic resonance imaging demonstrated that deletion of endothelial NRP1 suppressed neuron demyelination, altered lymphocyte infiltration, preserved BBB function and decreased activation of the STAT1–CXCL10 pathway. Furthermore, increased expression of NRP1 was observed in endothelial cells of acute multiple sclerosis lesions. Our data identify a new molecular mechanism of brain microvascular endothelial inflammatory response through NRP1–IFNγ crosstalk that could be a potential target for intervention of endothelial cell dysfunction in neuroinflammatory diseases.
Systematic review with meta‐analysis: prevalent vs. incident oesophageal adenocarcinoma and high‐grade dysplasia in Barrett's oesophagus
Visrodia, Kavel , Singh, Siddharth , Krishnamoorthi, Rajesh , Ahlquist, David A. , Wang, K. K., Iyer, Prasad G. , Katzka, David A.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 26, 2016 | Volume: 44 | Issue: 8 | Pages: 775-784

10.1111/apt.13783 | PMID 27562355 Get It

SummaryBackgroundThe proportion of oesophageal adenocarcinoma that is detected concurrently with initial Barrett's oesophagus diagnosis is not well studied.AimTo compare the proportion of prevalent adenocarcinoma vs. incident adenocarcinoma found during surveillance of Barrett's.MethodsWe performed a systematic search of MEDLINE, EMBASE and Web of Science (from their inception to 31 May 2015) for cohort studies in adults with Barrett's (nondysplastic Barrett's ± Barrett's with low‐grade dysplasia) with minimum average follow‐up of 3 years, and providing numbers of prevalent adenocarcinoma detected (concurrently with Barrett's diagnosis and up to 1 year afterwards) vs. incident adenocarcinoma detected (greater than 1 year after Barrett's diagnosis). Pooled weighted proportions of prevalent and incident adenocarcinoma were calculated, using a random effects model.ResultsOn meta‐analysis of 13 studies reporting on 603 adenocarcinomas in 9657 Barrett's patients, 85.1% of adenocarcinomas were classified as prevalent [95% confidence interval (CI), 78.1–90.2%) and 14.9% as incident (95% CI, 9.8–21.9%), with substantial heterogeneity (I2 = 66%). Among nine studies reporting on 787 high‐grade dysplasia and oesophageal adenocarcinomas in 8098 Barrett's patients, the proportion of prevalent high‐grade dysplasia‐oesophageal adenocarcinoma was similar at 80.5% (95% CI, 68.1–88.8%, I2 = 87%). These results remained stable across multiple subgroup analyses including study quality, setting, duration of follow‐up and presence of baseline dysplasia.ConclusionsIn our meta‐analysis, four of five patients diagnosed with adenocarcinoma or high‐grade dysplasia at index endoscopy or within 1 year of Barrett's follow‐up were considered to be prevalent cases. Continued efforts are needed to identify patients with Barrett's before the development of adenocarcinoma.
Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer
Painter, Jodie N. , O’Mara, Tracy A. , Marquart, Louise , Webb, Penelope M. , Medland, Sarah E. , Cheng, Timothy, Holliday, Elizabeth , McEvoy, Mark , Scott, Rodney J. , Healey, Catherine S., Shah, Mitul , Gorman, Maggie, Martin, Lynn , Hodgson, Shirley V. , Beckmann, Matthias W. , Ekici, Arif B. , Fasching, Peter A. , Hein, Alexander , Rübner, Matthias, Darabi, Hatef, Li, Jingmei , Dörk, Thilo , Hillemanns, Peter , Runnebaum, Ingo B. , Annibali, Daniela , Depreeuw, Jeroen, Lambrechts, Diether , Neven, Patrick , Cunningham, Julie M. , Dowdy, Sean C. , Goode, Ellen L. , Winham, Stacey J. , Njølstad, Tormund S. , Salvesen, Helga B., Trovik, Jone , Werner, Henrica M.J., Ashton, Katie A. , Otton, Geoffrey, Proietto, Anthony , Mints, Miriam, Tham, Emma , Bolla, Manjeet K. , Michailidou, Kyriaki , Wang, Qin , Hopper, John L. , Peto, Julian , Swerdlow, Anthony J. , Burwinkel, Barbara , Brenner, Hermann , Meindl, Alfons, Brauch, Hiltrud , Lindblom, Annika , Chang‐Claude, Jenny , Couch, Fergus J. , Kristensen, Vessela N. , Tomlinson, Ian M., Dunning, Alison M. , Easton, Douglas F. , Thompson, Deborah J. , Lambrechts, Diether , Attia, John , Dennis, Joe , Ahmed, Shahana , Czene, Kamila , Hall, Per N , Dürst, Matthias , Amant, Frédéric , Fridley, Brooke L. , Mints, Miriam , Tyrer, Jonathan P. , Meindl, Alfons, Couch, Fergus J. , Giles, Graham G. , Cox, Angela , Pharoah, Paul D.P. , Spurdle, Amanda B. , Winham, Stacey J , Dörk, Thilo , Lambrechts, Diether , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Swerdlow, Anthony J , Medland, Sarah E , O'Mara, Tracy A , Dunning, Alison M , Lambrechts, Diether , Brenner, Hermann , Li, Jingmei , Ekici, Arif B , Michailidou, Kyriaki , Brauch, Hiltrud , Lindblom, Annika

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | August 22, 2016 | Volume: 25 | Issue: 11 | Pages: 1503-1510

10.1158/1055-9965.epi-16-0147 | PMID 27550749 Get It

Abstract Background: The strongest known risk factor for endometrial cancer is obesity. To determine whether SNPs associated with increased body mass index (BMI) or waist–hip ratio (WHR) are associated with endometrial cancer risk, independent of measured BMI, we investigated relationships between 77 BMI and 47 WHR SNPs and endometrial cancer in 6,609 cases and 37,926 country-matched controls. Methods: Logistic regression analysis and fixed effects meta-analysis were used to test for associations between endometrial cancer risk and (i) individual BMI or WHR SNPs, (ii) a combined weighted genetic risk score (wGRS) for BMI or WHR. Causality of BMI for endometrial cancer was assessed using Mendelian randomization, with BMIwGRS as instrumental variable. Results: The BMIwGRS was significantly associated with endometrial cancer risk (P = 3.4 × 10−17). Scaling the effect of the BMIwGRS on endometrial cancer risk by its effect on BMI, the endometrial cancer OR per 5 kg/m2 of genetically predicted BMI was 2.06 [95% confidence interval (CI), 1.89–2.21], larger than the observed effect of BMI on endometrial cancer risk (OR = 1.55; 95% CI, 1.44–1.68, per 5 kg/m2). The association attenuated but remained significant after adjusting for BMI (OR = 1.22; 95% CI, 1.10–1.39; P = 5.3 × 10−4). There was evidence of directional pleiotropy (P = 1.5 × 10−4). BMI SNP rs2075650 was associated with endometrial cancer at study-wide significance (P < 4.0 × 10−4), independent of BMI. Endometrial cancer was not significantly associated with individual WHR SNPs or the WHRwGRS. Conclusions: BMI, but not WHR, is causally associated with endometrial cancer risk, with evidence that some BMI-associated SNPs alter endometrial cancer risk via mechanisms other than measurable BMI. Impact: The causal association between BMI SNPs and endometrial cancer has possible implications for endometrial cancer risk modeling. Cancer Epidemiol Biomarkers Prev; 25(11); 1503–10. ©2016 AACR.
Selenium Supplementation for Prevention of Colorectal Adenomas and Risk of Associated Type 2 Diabetes
Thompson, Patricia A. , Ashbeck, Erin L., Roe, Denise J. , Fales, Liane, Buckmeier, Julie A., Wang, Fang , Bhattacharyya, A. K. , Hsu, Chiu‐Hsieh , Chow, H.‐H. Sherry , Ahnen, Dennis J. , Heigh, Russell I., Fay, David E., Jacobs, Elizabeth T. , Alberts, David S., Lance, Peter , Buckmeier, Julie, Bhattacharyya, Achyut, Boland, C. Richard , Hamilton, Stanley R. , Martı́nez, Marı́a Elena

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 17, 2016 | Volume: 108 | Issue: 12 | Pages: No page available

10.1093/jnci/djw152 | PMID 27530657 Get It

Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial
Thompson, Patricia A. , Ashbeck, Erin L., Roe, Denise J. , Fales, Liane, Buckmeier, Julie A., Wang, Fang , Bhattacharyya, Achyut, Hsu, Chiu‐Hsieh , Chow, Sherry, Ahnen, Dennis J. , Heigh, Russell I., Fay, David E., Jacobs, Elizabeth T. , Alberts, David S., Lance, Peter , Buckmeier, Julie, Chow, Sherry H H, Boland, C. Richard , Hamilton, Stanley R. , Martinez, Elena Maria, Martínez, Elena

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 16, 2016 | Volume: 108 | Issue: 12 | Pages: No page available

10.1093/jnci/djw151 | PMID 27530656 Get It

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Gojo, Ivana , Pratz, Keith W. , McDevitt, Michael A. , Baer, Maria R. , Gore, Steven D. , Showel, Margaret M. , Gladstone, Douglas E. , Ji, Jiuping Jay, Wang, Lihua , Kinders, Robert J. , Pouquet, Marie , Walbi, Ismail A. , Poh, Weijie , Herman, James G. , Karnitz, Larry M., Chen, Alice P. , Karp, Judith E. , Kaufmann, Scott H. , Beumer, Jan Hendrik , Blackford, Amanda , Smith, B. Douglas , Carraway, Hetty E. , Levis, Mark J. , Dezern, Amy Elizabeth , Ji, Jiuping , Rudek, Michelle A. , Poh, Weijie

Mayo Clinic

Clinical Cancer Research | August 8, 2016 | Volume: 23 | Issue: 3 | Pages: 697-706

10.1158/1078-0432.ccr-16-0984 | PMID 27503200 Get It

Abstract Purpose: In preclinical studies, the PARP inhibitor veliparib enhanced the antileukemic action of temozolomide through potentiation of DNA damage. Accordingly, we conducted a phase 1 study of temozolomide with escalating doses of veliparib in patients with relapsed, refractory acute myeloid leukemia (AML) or AML arising from aggressive myeloid malignancies. Experimental Design: Patients received veliparib [20–200 mg once a day on day 1 and twice daily on days 4–12 in cycle 1 (days 1–8 in cycle ≥2)] and temozolomide [150–200 mg/m2 daily on days 3–9 in cycle 1 (days 1–5 in cycle ≥2)] every 28 to 56 days. Veliparib pharmacokinetics and pharmacodynamics [ability to inhibit poly(ADP-ribose) polymer (PAR) formation and induce H2AX phosphorylation] were assessed. Pretreatment levels of MGMT and PARP1 protein, methylation of the MGMT promoter, and integrity of the Fanconi anemia pathway were also examined. Results: Forty-eight patients were treated at seven dose levels. Dose-limiting toxicities were oral mucositis and esophagitis lasting >7 days. The MTD was veliparib 150 mg twice daily with temozolomide 200 mg/m2 daily. The complete response (CR) rate was 17% (8/48 patients). Veliparib exposure as well as inhibition of PAR polymer formation increased dose proportionately. A veliparib-induced increase in H2AX phosphorylation in CD34+ cells was observed in responders. Three of 4 patients with MGMT promoter methylation achieved CR. Conclusions: Veliparib plus temozolomide is well tolerated, with activity in advanced AML. Further evaluation of this regimen and of treatment-induced phosphorylation of H2AX and MGMT methylation as potential response predictors appears warranted. Clin Cancer Res; 23(3); 697–706. ©2016 AACR.
RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas
Blum, Andrew E., Venkitachalam, Srividya , Kieber-Emmons, Ann Marie, Ravi, Lakshmeswari, Chandar, Apoorva K., Iyer, Prasad G. , Wang, Jean S. , Shaheen, Nicholas J. , Barnholtz‐Sloan, Jill S. , Markowitz, Sanford D. , Willis, Joseph , Shyr, Yu , Chak, Amitabh , Varadan, Vinay , Guda, Kishore , Guo, Yan Ping , Canto, Marcia Irene , Willis, Joseph E , Barnholtz-Sloan, Jill S

Mayo Clinic

Cancer Research | August 8, 2016 | Volume: 76 | Issue: 19 | Pages: 5628-5633

10.1158/0008-5472.can-16-0979 | PMID 27503924 Get It

Abstract Esophageal adenocarcinoma is a deadly cancer with increasing incidence in the United States, but mechanisms underlying pathogenesis are still mostly elusive. In addressing this question, we assessed gene fusion landscapes by comprehensive RNA sequencing (RNAseq) of 55 pretreatment esophageal adenocarcinoma and 49 nonmalignant biopsy tissues from patients undergoing endoscopy for Barrett's esophagus. In this cohort, we identified 21 novel candidate esophageal adenocarcinoma–associated fusions occurring in 3.33% to 11.67% of esophageal adenocarcinomas. Two candidate fusions were selected for validation by PCR and Sanger sequencing in an independent set of pretreatment esophageal adenocarcinoma (N = 115) and nonmalignant (N = 183) biopsy tissues. In particular, we observed RPS6KB1–VMP1 gene fusion as a recurrent event occurring in approximately 10% of esophageal adenocarcinoma cases. Notably, esophageal adenocarcinoma cases harboring RPS6KB1–VMP1 fusions exhibited significantly poorer overall survival as compared with fusion-negative cases. Mechanistic investigations established that the RPS6KB1–VMP1 transcript coded for a fusion protein, which significantly enhanced the growth rate of nondysplastic Barrett's esophagus cells. Compared with the wild-type VMP1 protein, which mediates normal cellular autophagy, RPS6KB1–VMP1 fusion exhibited aberrant subcellular localization and was relatively ineffective in triggering autophagy. Overall, our findings identified RPS6KB1–VMP1 as a genetic fusion that promotes esophageal adenocarcinoma by modulating autophagy-related processes, offering new insights into the molecular pathogenesis of esophageal adenocarcinomas. Cancer Res; 76(19); 5628–33. ©2016 AACR.
Profibrotic up‐regulation of glucose transporter 1 by TGF‐β involves activation of MEK and mammalian target of rapamycin complex 2 pathways
Andrianifahanana, Mahefatiana, Hernandez, Danielle M. , Yin, Xueqian , Kang, Jeong Han , Yi, Eunhee S. , Roden, Anja C. , Leof, Edward B. , Jung, Mi-Yeon, Wang, Youli, Jung, Miyeon , Wang, Youli , Limper, Andrew H.

Mayo Clinic

The FASEB Journal | August 1, 2016 | Volume: 30 | Issue: 11 | Pages: 3733-3744

10.1096/fj.201600428r | PMID 27480571 Get It

ABSTRACT TGF‐β plays a central role in the pathogenesis of fibroproliferative disorders. Defining the exact underlying molecular basis is therefore critical for the development of viable therapeutic strategies. Here, we show that expression of the facilitative glucose transporter 1 (GLUT1) is induced by TGF‐β in fibroblast lines and primary cells and is required for the profibrotic effects of TGF‐β. In addition, enhanced GLUT1 expression is observed in fibrotic areas of lungs of both patients with idiopathic pulmonary fibrosis and mice that are subjected to a fibrosis‐inducing bleomycin treatment. By using pharmacologic and genetic approaches, we demonstrate that up‐regulation of GLUT1 occurs via the canonical Smad2/3 pathway and requires autocrine activation of the receptor tyrosine kinases, platelet‐derived and epidermal growth factor receptors. Engagement of the common downstream effector PI3K subsequently triggers activation of the MEK and mammalian target of rapamycin complex 2, which cooperate in regulating GLUT1 expression. Of note, inhibition of GLUT1 activity and/or expression is shown to impair TGFβ–driven fibrogenic processes, including cell proliferation and production of profibrotic mediators. These findings provide new perspectives on the interrelation of metabolism and profibrotic TGF‐β signaling and present opportunities for potential therapeutic intervention.—Andrianifahanana, M., Hernandez, D. M., Yin, X., Kang, J.‐H., Jung, M.‐Y., Wang, Y., Yi, E. S., Roden, A. C., Limper, A. H., Leof, E. B. Profibrotic up‐regulation of glucose transporter 1 by TGF‐β involves activation of MEK and mammalian target of rapamycin complex 2 pathways. FASEB J. 30, 3733–3744 (2016) www.fasebj.org
Nocturnal Hypoxemia Due to Obstructive Sleep Apnea Is an Independent Predictor of Poor Prognosis After Myocardial Infarction
Xie, Jiang , Covassin, Naima , Singh, Prachi , Gami, Apoor S., Wang, Shihan , Chahal, C. Anwar A. , Wei, Yongxiang , Sert Kuniyoshi, Fatima H, Kuniyoshi, Fatima H. Sert , Somers, Virend K. , Chahal, Choudhary Anwar A , Singh, Prachi

Mayo Clinic

Journal of the American Heart Association | July 27, 2016 | Volume: 5 | Issue: 8 | Pages: No page available

10.1161/jaha.115.003162 | PMID 27464791 Get It

Background Obstructive sleep apnea ( OSA ) is an important risk factor for the development of cardiovascular diseases including myocardial infarction ( MI ). The aim of this study was to investigate the effects of OSA on prognosis after MI , and to determine which specific measures of OSA severity best predicted outcomes. Methods and Results We performed a prospective study, in which 112 patients without a prior diagnosis of sleep apnea underwent comprehensive polysomnography within a median of 7 days after MI . Patients were followed up at 6‐monthly intervals (±2 weeks) for a total of 48 months. Patients classified with central apnea (n=6) or those using continuous positive airway pressure (n=8) after polysomnography were excluded from analyses. The primary end point was major adverse cardiac events, including death from any cause, recurrent MI , unstable angina, heart failure, stroke, and significant arrhythmic events. Forty of 98 patients (41%) had OSA (apnea‐hypopnea index ≥15 events/h). OSA patients had higher major adverse cardiac event rates when compared to those without OSA (47.5% versus 24.1%; χ 2 =5.41, P =0.020). In a multivariate model that adjusted for clinically relevant variables including age, left ventricular ejection fraction, diabetes mellitus, oxygen desaturation index, and arousal index, significant hypoxemia, as defined by nocturnal nadir oxygen saturation ≤85%, was an independent risk factor for major adverse cardiac events (hazard ratio=6.05, P =0.004) in follow‐up 15 months after baseline. Conclusions Nocturnal hypoxemia in OSA is an important predictor of poor prognosis for patients after MI . These findings suggest that routine use of low‐cost nocturnal oximetry may be an economical and practical approach to stratify risk in post‐ MI patients.